The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental ...

ImmuneSensor begins patient dosing in phase 1 trial of lead cGAS inhibitor drug candidate, IMSB301 to treat inflammatory and autoimmune diseases: Dallas, Texas Thursday, October 1 ...

Research over the past decade has revealed multiple potential mechanisms by which dendritic cells contribute to the immunopathogenesis of systemic lupus erythematosus. Genetic abnormalities in ...

The potent extrafollicular B cell response and activated GZMK + CD8 T cells may form a vicious circle and unique ecosystem, which may underlie the pathogenesis in lupus kidney. These findings may ...

To date, treatment with NIM-1324 has reduced the production of interferon alpha in human peripheral blood mononuclear cells (PBMCs) from systemic lupus erythematosus (SLE) patients and provided ...

Women diagnosed with premature ovarian insufficiency (POI) have an increased prevalence of severe autoimmune diseases.

Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement of IMSB301 into Phase 1b/2 clinical ...

Future Rheumatol. 2008;3(3):269-279.

Patients affected by Lupus Nephritis still suffer from high risk of morbidity ... The use of ML may also represent a turning point in understanding the complex mechanisms underlying the pathogenesis ...